TheraRadar
← Back
Data updated: Mar 29, 2026

RHYTHM

MetabolicCardiovascularInfectious Disease
Pharma

RHYTHM is a pharmaceutical company focused on Metabolic, Cardiovascular, Infectious Disease. Key products include IMCIVREE.

2020
Since
1
Drugs
-
Trials
2
Approved (2yr)

Key Drugs

IMCIVREE
setmelanotide acetate
Metabolic
MC4R 5 indications · 2020

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

IMCIVREE 2025-08-21
Labeling
IMCIVREE 2024-12-20
Efficacy
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 91%
1 drugs Phase 3: 7 Phase 2: 8 Phase 1: 1
Cardiovascular 7%
0 drugs Phase 3: 1
Infectious Disease 2%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Merck big-pharma
Infectious Disease, Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Infectious Disease, Cardiovascular, Metabolic
B BRAUN specialty
Infectious Disease, Metabolic, Cardiovascular
Novo Nordisk big-pharma
Metabolic, Cardiovascular, Infectious Disease
AZURITY specialty
Cardiovascular, Metabolic, Infectious Disease